1. Home
  2. IVDA vs HCWB Comparison

IVDA vs HCWB Comparison

Compare IVDA & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iveda Solutions Inc.

IVDA

Iveda Solutions Inc.

N/A

Current Price

$0.19

Market Cap

3.7M

Sector

Technology

ML Signal

N/A

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

N/A

Current Price

$0.78

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IVDA
HCWB
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
3.6M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
IVDA
HCWB
Price
$0.19
$0.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 115.8K
34.9K
Earning Date
11-16-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 51.38
N/A
EPS
★ N/A
N/A
Revenue
★ $4,468,279.00
$4,099,750.00
Revenue This Year
N/A
$12,215.61
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.74
52 Week High
$1.52
$23.94

Technical Indicators

Market Signals
Indicator
IVDA
HCWB
Relative Strength Index (RSI) 33.66 23.34
Support Level $0.18 N/A
Resistance Level $0.34 $1.28
Average True Range (ATR) 0.02 0.09
MACD -0.00 0.01
Stochastic Oscillator 10.87 1.34

Price Performance

Historical Comparison
IVDA
HCWB

About IVDA Iveda Solutions Inc.

Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: